SCHEMBL6370407

SCHEMBL6370407

CN1CCN(CCCNC(=O)c2ccc(-c3n[nH]c4cc(Nc5ccccc5Cl)ccc34)cc2)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 13/20 0.73
MAPK10 P53779 11/20 0.73
MAPK14 Q16539 10/20 0.73
MAPK13 O15264 1/20 0.52
MAPK12 P53778 1/20 0.52
MAPK11 Q15759 1/20 0.52
KDM4E B2RXH2 2/20 0.49
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
DRD3 P35462 1/20 0.47
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
AHR P35869 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6370630 0.92 MAPK8 (0.86) MAPK8MAPK10MAPK14MAPK13MAPK12
SCHEMBL6370349 0.87 MAPK8 (0.78) MAPK8MAPK10MAPK14MAPK13MAPK12
SCHEMBL6370605 0.86 MAPK8 (0.87) MAPK8MAPK10MAPK14MAPK13MAPK12
SCHEMBL6370442 0.85 MAPK8 (0.90) MAPK8MAPK10MAPK14KDM4EALDH1A1
SCHEMBL6370609 0.84 MAPK10 (1.00) MAPK8MAPK10MAPK14MAPK13MAPK12
SCHEMBL6422935 0.83 MAPK8 (1.00) MAPK8MAPK10MAPK14HPGD
SCHEMBL6370498 0.81 MAPK8 (0.78) MAPK8MAPK10MAPK14MAPK13MAPK12
SCHEMBL6377559 0.79 MAPK8 (0.91) MAPK8MAPK10MAPK14MAPK13MAPK12
SCHEMBL6369545 0.77 MAPK10 (0.70) MAPK8MAPK10MAPK14
SCHEMBL6375883 0.77 MAPK8 (0.90) MAPK8MAPK10MAPK14KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US claimed
EP-1476432-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES AstraZeneca AB (SE) 2004-11-17 EP claimed
WO-2003068754-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-08-21 WO claimed
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US disclosed
EP-1476432-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES AstraZeneca AB (SE) 2004-11-17 EP disclosed
WO-2003068754-A1 THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113370-A1 Therapeutic substituted indazole derivatives NR4A3, CBR3, NR3C2 MAPK8 1582/4885MAPK10 2059/4885MAPK14 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.